pharma · Advanced Solid Tumors · Advanced Solid Tumor · MDNAF
Medicenna Therapeutics
Medicenna Therapeutics patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Toronto, CA
- Employees
- 24
- Programs
- 3
- Drugs
- 3
- Patents
- 9
Medicenna Therapeutics patents
9 pharmaceutical patents indexed for Medicenna Therapeutics. 0 expire within 24 months.
Medicenna Therapeutics has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12404497
Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
granted -
US 12338269
IL-2 superagonists in combination with anti-PD-1 antibodies
granted -
US 12274735
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
granted -
US 11680090
Interleukin-2 fusion proteins and uses thereof
granted -
US 11542312
IL-2 superagonists in combination with anti-PD-1 antibodies
granted -
US 11352402
Interleukin-4 receptor-binding fusion proteins and uses thereof
granted -
US 10781242
Interleukin-2 fusion proteins and uses thereof
granted -
US 10106592
Interleukin-4 receptor-binding fusion proteins and uses thereof
granted -
US 10093708
Interleukin-4 receptor-binding fusion proteins and uses thereof
granted
Frequently asked questions
How many patents does Medicenna Therapeutics have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Medicenna Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.